These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 12811107)

  • 1. Drug policy: making effective drugs available without bankrupting the healthcare system.
    Laupacis A; Anderson G; O'Brien B
    Healthc Pap; 2002; 3(1):12-30. PubMed ID: 12811107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug use in Bangladesh: policy versus practice.
    Islam MS
    Indian J Med Ethics; 2008; 5(1):24-5. PubMed ID: 18630250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of China's national essential medicines policy.
    Guan X; Liang H; Xue Y; Shi L
    J Public Health Policy; 2011 Aug; 32(3):305-19. PubMed ID: 21614030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug policy: the challenge is to overcome fragmentation.
    McFarlance A
    Healthc Pap; 2002; 3(1):38-42: discussion 87-94. PubMed ID: 12811109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inverse benefit law: how drug marketing undermines patient safety and public health.
    Brody H; Light DW
    Am J Public Health; 2011 Mar; 101(3):399-404. PubMed ID: 21233426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The essential drugs concept is needed now more than ever.
    Smith MK; Tickell S
    Trans R Soc Trop Med Hyg; 2003; 97(1):2-5. PubMed ID: 12886792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Let evidence be the arbiter.
    Lindberg MC
    Healthc Pap; 2002; 3(1):43-6; discussion 87-94. PubMed ID: 12811110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug policy: an oxymoron?
    Gray J
    Healthc Pap; 2002; 3(1):56-62; discussion 87-94. PubMed ID: 12811112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Getting the cat back in the bag: reforming the way provinces manage drug expenditures to make them manageable.
    Levy AR; Gagnon YM
    Healthc Pap; 2002; 3(1):32-7; discussion 87-94. PubMed ID: 12811108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Common Drug Review: a NICE start for Canada?
    McMahon M; Morgan S; Mitton C
    Health Policy; 2006 Aug; 77(3):339-51. PubMed ID: 16214257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Access to medicines and global health: will Canada lead or flounder?
    Orbinski J
    CMAJ; 2004 Jan; 170(2):224-6. PubMed ID: 14734437
    [No Abstract]   [Full Text] [Related]  

  • 13. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acceptability and feasibility of a national essential medicines list in Canada: a qualitative study of perceptions of decision-makers and policy stakeholders.
    Jarvis JD; Murphy A; Perel P; Persaud N
    CMAJ; 2019 Oct; 191(40):E1093-E1099. PubMed ID: 31591095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More of the same is not enough.
    Willison DJ
    Healthc Pap; 2002; 3(1):47-55; discussion 87-94. PubMed ID: 12811111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of availability, accessibility and prescribing pattern of medicines in the Islamic Republic of Iran.
    Cheraghali AM; Nikfar S; Behmanesh Y; Rahimi V; Habibipour F; Tirdad R; Asadi A; Bahrami A
    East Mediterr Health J; 2004 May; 10(3):406-15. PubMed ID: 16212218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing healthcare costs within an integrated framework.
    Fernandes R
    Healthc Pap; 2002; 3(1):70-6; discussion 87-94. PubMed ID: 12811114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.
    Babar ZU; Gammie T; Seyfoddin A; Hasan SS; Curley LE
    Res Social Adm Pharm; 2019 Mar; 15(3):231-243. PubMed ID: 29678413
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.